Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies

Acta Psychiatrica Scandinavica

Volumn 122, Issue 6, 2010, Pages 444-453

  Davies, S J C ^a   Westin, A A ^b   Castberg, I ^b,c   Lewis, G ^a   Lennard, M S ^d   Taylor, S ^d   Spigset, O ^b,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Fluoxetine; Interactions; Metabolism; Paroxetine; Zuclopenthixol

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; FLUOXETINE; KETOCONAZOLE; LEVOMEPROMAZINE; PAROXETINE; QUINIDINE; ZUCLOPENTHIXOL;

ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIFUNGAL AGENTS; ANTIMALARIALS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; CLOPENTHIXOL; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; FLUOXETINE; HUMANS; KETOCONAZOLE; MALE; METHOTRIMEPRAZINE; MICROSOMES, LIVER; MIDDLE AGED; PAROXETINE; QUINIDINE;

EID: 78149388927     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01619.x     Document Type: Article

References (26)

1. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry 1994;2:204-213.
2. Davies SJC, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult and functional elderly psychiatric wards. Br J Clin Pharmacol 2004;57:464-472.
3. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
4. Dahl ML, Ekqvist B, Widen J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991;84:99-102.
5. Jerling M, Dahl ML, Aberg-Wistedt A et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-428.
6. Jaanson P, Marandi T, Kiivet RA et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002;162: 67-73.
7. Linnet K, Wiborg O. Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1995;17:308-311.
8. Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf 2006;29:95-118.
9. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265.
10. Nemeroff CB, Devane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320.
11. Suzuki A, Otani K, Ishida M et al. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit 1997;19:261-264.
12. Bertilsson L, Tybring G, Widén J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 1997;44:186-189.
13. Shaw L, Lennard MS, Tucker GT, Bax ND, Woods HF. Irreversible binding and metabolism of propranolol by human liver microsomes-relationship to polymorphic oxidation. Biochem Pharmacol 1987;36:2283-2288.
14. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409.
15. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995;25:261-270.
16. Hansen BB, Hansen SH. Determination of zuclopenthixol and its main N-dealkylated metabolite in biological fluids using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection. J Chromatogr B Biomed Appl 1994;658:319-325.
17. Zar JH. Biostatistical analysis, 2nd edn. Englewood Cliffs, NJ: Prentice-Hall, 1984.
18. Stockley IH. Drug interactions, 8th edn. The Pharmaceutical Press, 2007.
19. Davies SJ, Lennard MS, Ghahramani P, Pratt P, Robertson A, Potokar J. PRN prescribing in psychiatric inpatients - potential for pharmacokinetic drug interactions. J Psychopharm 2007;21:153-160.
20. Gonzalez FJ, Skoda RC, Kimura S et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-446.
21. Buckley N, Mcmanus P. Fatal toxicity of drugs used in the treatment of psychotic illnesses. Br J Psychiatry 1988;172: 461-464.
22. Royal College of Psychiatrists Psychopharmacology Sub-Group. The Association between antipsychotic drugs and sudden death. Council Report CR57. Royal College of Psychiatrists, 1997.
23. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev 2005;4: CD005474.
24. Hood SD, Orr K, Bennett L, Davies SJC. Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. Australas Psychiatry 2010;18:174-176.
25. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 10th edn. London: Informa HealthCare, 2009.
26. National Institute For Clinical Excellence. Violence. The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. Clinical Guideline 25.